AMGEN Inc (AMGN) concluded trading on Wednesday at a closing price of $273.41, with 4.47 million shares of worth about $1.22 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.19% during that period and on December 11, 2024 the price saw a loss of about -0.85%. Currently the company’s common shares owned by public are about 537.50M shares, out of which, 536.25M shares are available for trading.
Stock saw a price change of -1.74% in past 5 days and over the past one month there was a price change of -15.04%. Year-to-date (YTD), AMGN shares are showing a performance of -5.07% which increased to 0.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $257.80 but also hit the highest price of $346.85 during that period. The average intraday trading volume for AMGEN Inc shares is 2.82 million. The stock is currently trading -3.34% below its 20-day simple moving average (SMA20), while that difference is down -10.26% for SMA50 and it goes to -10.47% lower than SMA200.
AMGEN Inc (NASDAQ: AMGN) currently have 537.50M outstanding shares and institutions hold larger chunk of about 78.09% of that.
The stock has a current market capitalization of $146.97B and its 3Y-monthly beta is at 0.55. PE ratio of stock for trailing 12 months is 35.01, while it has posted earnings per share of $7.81 in the same period. Its PEG reads 7.00 and has Quick Ratio of 0.96 while making debt-to-equity ratio of 8.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMGN, volatility over the week remained 2.11% while standing at 2.91% over the month.
Stock’s fiscal year EPS is expected to rise by 5.02% while it is estimated to increase by 5.72% in next year. EPS is likely to grow at an annualized rate of 5.00% for next 5-years, compared to annual growth of -0.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 10, 2024 offering an Underperform rating for the stock and assigned a target price of $256 to it. On November 14, 2024, Citigroup Initiated their recommendations, while on October 17, 2024, Bernstein Initiated their ratings for the stock with a price target of $380. Stock get a Hold rating from Truist on October 14, 2024.
